Renal Denervation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, and Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, and O

Global Renal Denervation Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. It can be ascribed to increasing innovation of renal denervation system, increase in hypertension cases due to consuming alcohol, and unhealthy foods, growing usage of the endovascular catheter, radiofrequency ablation, and the continuous rise in the number of heart failure cases. However, increasing funding for R&D activities for treating renal abnormalities by various regulators and some state governments and the significant number of benefits of this method, along with the increasing efforts and initiatives being launched by influential Market players, will propel the market in the forecast period. The occurrence of hypertension has increased from 17,307 per 100,000 in 1990 to 20,525 per 100,000 in 2015. The rising burden of chronic diseases like obesity among children and adults will power renal denervation market trends through the forecast period. The global renal denervation market is a rapidly growing industry that involves the use of advanced medical technologies to treat hypertension, or high blood pressure. Renal denervation is a minimally invasive procedure that uses radiofrequency ablation to disable the nerves that surround the kidneys. By doing so, the body's natural response to high blood pressure is reduced, leading to a decrease in blood pressure levels.

Rising incidence of hypertension among people

With the increasing modernization worldwide, people's lifestyles are majorly being changed. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. The prevalence of hypertension has been observing a substantial rise over the past few years. Because more strict BP objectives are recommended by guidelines, obtaining these targets necessitates using multiple drugs, resulting in increased dosing complexity, expense, pill burden, and drug intolerance. Some significant reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet. The rising number of geriatrics worldwide is one of the primary reasons for an increase in the risk of hypertension. According to the World Health Organization, 2021, around 1.28 billion people aged between 30 and 79 are globally affected by hypertension. Renal denervation has been shown to be an effective treatment for hypertension, leading to an increase in demand for the procedure. As people age, the risk of developing hypertension increases. The world's population is aging rapidly, and this is contributing to the increasing prevalence of hypertension. The consumption of a diet high in salt, sugar, and saturated fats is a major risk factor for hypertension. The modern lifestyle has led to an increase in the consumption of processed and fast foods, which are often high in salt, sugar, and saturated fats. Lack of physical activity is another risk factor for hypertension. The modern lifestyle has led to a decrease in physical activity levels, leading to an increase in the prevalence of hypertension. Obesity is a major risk factor for hypertension. The prevalence of obesity is increasing across the globe, contributing to the increasing prevalence of hypertension. Hypertension can also be caused by genetic factors. Some people are more susceptible to hypertension due to their genetic makeup. Chronic stress can also contribute to the development of hypertension. Stress activates the sympathetic nervous system, leading to an increase in blood pressure. Smoking and alcohol consumption are also risk factors for hypertension. The prevalence of smoking and alcohol consumption is high in several countries, contributing to the increasing prevalence of hypertension. The increasing prevalence of hypertension across the globe is a result of several factors, including aging population, unhealthy diet, sedentary lifestyle, obesity, genetics, chronic stress, smoking, and alcohol consumption.

Rising demand for minimally invasive procedures

Minimally invasive procedures are becoming increasingly popular due to their many benefits, including faster recovery time, less pain, and reduced risk of complications. Renal denervation is a minimally invasive procedure that involves the use of a small catheter that is inserted through a small incision in the groin. This has led to an increase in demand for renal denervation procedures. Minimally invasive procedures are less invasive than traditional surgical procedures and involve smaller incisions. This leads to faster recovery times for patients, who can return to their normal activities more quickly. Minimally invasive procedures are associated with less pain than traditional surgical procedures, as they involve smaller incisions and less tissue damage. Minimally invasive procedures have a lower risk of complications than traditional surgical procedures, as they involve smaller incisions and less tissue damage. Minimally invasive procedures are often performed on an outpatient basis, which means that patients do not need to stay in the hospital for an extended period. This reduces the cost of the procedure and the burden on the healthcare system. Minimally invasive procedures have been shown to improve patient outcomes, including reduced pain, improved quality of life, and reduced risk of complications.

Advancement of Renal Denervation

Almost about 47% adults in the United States have hypertension, who have a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension. Only about 1 in 4 adults (24%) with hypertension have their condition under control.

Increase in research and development Activities

Research and development activities in the field of renal denervation are increasing rapidly, leading to the development of new and innovative technologies for the treatment of hypertension. This is expected to further fuel market growth in the coming years. Governments in several countries are taking initiatives to promote healthcare, including the treatment of hypertension. For instance, in the United States, the Centers for Medicare and Medicaid Services (CMS) has approved reimbursement for renal denervation procedures, making it more accessible to patients. Several companies have developed next-generation renal denervation devices that use advanced technologies to deliver more precise and effective treatment. These devices use ultrasound, radiofrequency, or other forms of energy to ablate the nerves in the renal arteries, reducing blood pressure and improving patient outcomes. Recent studies have shown that the response to renal denervation varies among patients, and that some patients may not respond to the treatment at all. To address this, researchers are exploring the use of personalized treatment approaches, such as identifying biomarkers or using imaging techniques to guide the selection of patients who are most likely to benefit from the procedure.

Recent Development

• EnligHTN Renal Denervation SystemThis system, developed by Boston Scientific, is a next-generation renal denervation device that uses radiofrequency energy to ablate the nerves in the renal arteries. It received CE mark approval in Europe in 2020 and is currently undergoing clinical trials in the United States.
• Vessix Renal Denervation SystemThis system, developed by Mercator MedSystems, is a minimally invasive renal denervation device that uses pulsed ultrasound to ablate the nerves in the renal arteries. It received CE mark approval in Europe in 2020 and is currently undergoing clinical trials in the United States.

Market Segmentation

In terms of country, the United States region dominates the global renal denervation market. According to CDC, in 2021, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

Market Players

Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited are some of the leading players operating in the Global Renal Denervation Market.